HealthTech funding in Morocco: ABA Life secures MAD 400 million from Admaius to finance medical AI and international growth. What the deal says about funding.
On October 26, 2026, Médias24 reported that ABA Life, the healthcare division of ABA Technology, had signed a MAD 400 million investment agreement with Admaius Capital Partners.
The amount is significant for a Moroccan technology company. But the real story lies elsewhere: in what this capital is meant to finance, and in how it will be turned into growth.
A funding round built around three priorities
According to Médias24, the investment is structured around three areas:
- artificial intelligence applied to healthcare, by accelerating the “AI for Sovereign Health” program, notably through Mediot AI and new clinical intelligence solutions;
- industrialization of the group’s technologies, their large-scale deployment and the development of its healthcare infrastructure and services;
- international expansion.
The “Fusion AI for Sovereign Health” program itself rests on five pillars: augmented telemedicine, predictive and precision medicine, AI-accelerated therapeutic innovation, a health-resilience platform able to anticipate pandemic risks, and an operational unit dedicated to field interventions.
In other words, this is not a round for a single product. It is a round to fund several projects at once.
Why raise equity rather than debt?
Mohamed Benouda, founder and chairman of ABA Technology, sums it up in his statement to Médias24: AI projects in medical diagnosis and telemedicine, as well as research and development, “require significant capital”.
That is precisely the kind of spending that fits poorly with debt.
R&D generates revenue later, sometimes much later. A bank loan requires regular repayments from the very first months. Funding innovation with equity aligns the financing timeline with the value-creation timeline.
In return, the company opens its capital. Médias24 does not disclose the stake acquired by Admaius. But in any deal of this kind, a new investor comes with clear expectations: visibility on the use of funds, performance milestones and an exit perspective.
What kind of investor is behind the deal?
Admaius Capital Partners is described as a pan-African investor specializing in healthcare, digital infrastructure and financial services.
That profile matters. A sector investor brings more than money: it brings market insight, a network and a demand for discipline. Admaius presents the deal as a step towards building an integrated HealthTech player, highlighting ABA Life’s business model, technological capabilities and growth potential beyond its current markets.
For the company, the quality of the investor often matters as much as the amount raised.
Going international through acquisitions: a different finance job
The founder explains that international expansion should notably rely on acquisitions and external growth deals in target markets, with the ambition of sharing the experience gained with other African countries and emerging markets.
Buying a company abroad requires very different financial skills from those needed to run a domestic business:
- valuing targets and negotiating a price;
- running financial, tax and legal due diligence;
- structuring the financing of each deal;
- managing several currencies, tax systems and accounting standards;
- consolidating accounts and steering group cash.
At that stage, finance stops being a control function. It becomes a strategic steering function. This is the shift we described for companies moving from Casablanca to a multinational.
Industrializing often costs more than designing
The second priority, industrialization and large-scale deployment, is often the most capital-intensive.
A working prototype is not a deployed service. In between, a company needs equipment, infrastructure, deployment teams, maintenance and quality processes, which are even more demanding in healthcare.
The founder notes that the company has already introduced biomedical equipment in Morocco and used it in several use cases. The next step is to move from use cases to a repeatable model. That is where profitability is decided: in the ability to deploy faster than costs grow.
What the finance function must lock down after a funding round
A funding round is not an end. It is the start of a period in which every dirham must be traceable. For a finance department, several priorities emerge:
- a clear allocation plan across AI, industrialization and international growth;
- milestones shared with the investor and linked to the budget;
- monthly cash monitoring, with several scenarios;
- a foreign-exchange policy as soon as the business becomes multi-country;
- reporting to the standard expected by an investment fund.
This is often when a company needs to strengthen its finance function, or even recruit a CFO able to engage with investors and lead external growth deals.
A signal for HealthTech in Morocco
Beyond ABA Life, the deal shows that a healthcare technology company can attract a specialized investor for a project led from Morocco, with a stated ambition of “sovereign and accessible” solutions.
It comes as the healthcare sector faces strong capacity constraints, as we discussed regarding the 8,000 budgeted positions planned for 2027. Technology does not replace that capacity, but it can help use it differently.
One question will decide the success of the deal: execution.
Raising funds shows that a project is convincing. Execution shows that it delivers. Capital raised from investors or on the stock market is never enough on its own, as the T2S IPO also illustrated.
Is your company preparing a funding round, an acquisition or an international expansion, and does it need to structure its finance function? Our finance recruitment firm can help. Tell us about your needs.
Frequently asked questions
How much did ABA Life raise, and from whom?
ABA Life, the healthcare division of ABA Technology, signed a MAD 400 million investment agreement with Admaius Capital Partners, a pan-African investor specializing in healthcare, digital infrastructure and financial services.
What will the funds be used for?
Three priorities: accelerating the “AI for Sovereign Health” healthcare AI program, industrializing and deploying the group’s technologies, and expanding internationally, notably through external growth.
Why do HealthTech companies favor equity funding?
Because R&D and industrialization generate revenue late. Equity does not require immediate repayment, unlike debt, in exchange for opening the capital and meeting reporting requirements.
News source: Médias24, “HealthTech: ABA Life raises MAD 400 million from Admaius to finance its development” (in French), October 26, 2026.